⚡️🇺🇸#SAGE #отчетность
Sage Therapeutics reports third quarter 2021 results
Q3 GAAP EPS of -$2.21 misses by $0.36.
Revenue of $1.44M (-12.2% Y/Y) misses by $0.53M.
Sage Therapeutics reports third quarter 2021 results
Q3 GAAP EPS of -$2.21 misses by $0.36.
Revenue of $1.44M (-12.2% Y/Y) misses by $0.53M.
⚠️🇺🇸🇨🇳#YHOO #китай
Yahoo уходит из Китая после 20 лет любви
Yahoo Pulls Out of China, Ending Tumultuous Two-Decade Relationship
Yahoo уходит из Китая после 20 лет любви
Yahoo Pulls Out of China, Ending Tumultuous Two-Decade Relationship
⚡️🇺🇸#PFE #отчетность
Pfizer reports third quarter 2021 results
Q3 Non-GAAP EPS of $1.34 beats by $0.25;
GAAP EPS of $1.42 beats by $0.39.
Revenue of $24.1B (+134.4% Y/Y) beats by $1.28B
#прогноз Raises Full-Year 2021 Guidance for Revenues to a Range of $81.0 to $82.0 Billion from prior guidance of $78B-$80B vs. $81.56B
Pfizer reports third quarter 2021 results
Q3 Non-GAAP EPS of $1.34 beats by $0.25;
GAAP EPS of $1.42 beats by $0.39.
Revenue of $24.1B (+134.4% Y/Y) beats by $1.28B
#прогноз Raises Full-Year 2021 Guidance for Revenues to a Range of $81.0 to $82.0 Billion from prior guidance of $78B-$80B vs. $81.56B
⚡️🇺🇸#EL #отчетность
Estee Laude reports third quarter 2021 results
Non-GAAP EPS of $1.89 beats by $0.19;
GAAP EPS of $1.88 beats by $0.26.
Revenue of $4.39B (+23.3% Y/Y) beats by $140M
#прогноз sees Q2 EPS $2.51-$2.61, consensus $2.81
Estee Laude reports third quarter 2021 results
Non-GAAP EPS of $1.89 beats by $0.19;
GAAP EPS of $1.88 beats by $0.26.
Revenue of $4.39B (+23.3% Y/Y) beats by $140M
#прогноз sees Q2 EPS $2.51-$2.61, consensus $2.81
⚡️🇺🇸#ARNC #отчетность
Arconic reports third quarter 2021 results
Q3 GAAP EPS of $0.15 misses by $0.37.
Revenue of $1.89B (+33.1% Y/Y) misses by $50M
Arconic reports third quarter 2021 results
Q3 GAAP EPS of $0.15 misses by $0.37.
Revenue of $1.89B (+33.1% Y/Y) misses by $50M
⚡️🇺🇸#GPN #отчетность
Global Payments Reports Third Quarter 2021 Results
Delivers Record Third Quarter Results
Q3 adjusted EPS $2.18, consensus $2.14
#прогноз sees FY21 adjusted EPS $8.10-$8.20, consensus $8.02
Global Payments Reports Third Quarter 2021 Results
Delivers Record Third Quarter Results
Q3 adjusted EPS $2.18, consensus $2.14
#прогноз sees FY21 adjusted EPS $8.10-$8.20, consensus $8.02
⚡️🇺🇸#COP #отчетность
ConocoPhillips reports third quarter 2021 results
- Cash Flows From Ops: $4.8B (exp $4.36B)
- Adj EPS: $1.77 (exp $1.52)
- Production Ex-Libya 1,507M B/D
ConocoPhillips reports third quarter 2021 results
- Cash Flows From Ops: $4.8B (exp $4.36B)
- Adj EPS: $1.77 (exp $1.52)
- Production Ex-Libya 1,507M B/D
⚡️🇺🇸#INCY #отчетность
Incyte reports third quarter 2021 results
Q3 Non-GAAP EPS of $1.18 beats by $0.43;
GAAP EPS of $0.82 beats by $0.27.
Revenue of $812.98M (+31.0% Y/Y) beats by $68.45M
Incyte reports third quarter 2021 results
Q3 Non-GAAP EPS of $1.18 beats by $0.43;
GAAP EPS of $0.82 beats by $0.27.
Revenue of $812.98M (+31.0% Y/Y) beats by $68.45M
⚡️❗️🛢🇪🇺#газ #GAZP #транзит #украина
ГАЗПРОМ НЕ СТАЛ БРОНИРОВАТЬ ДОПМОЩНОСТИ ПО УКРАИНСКОМУ ТРАНЗИТУ ЧЕРЕЗ СТАНЦИЮ СУДЖА НА 1 КВ 22Г
ГАЗПРОМ НЕ СТАЛ БРОНИРОВАТЬ ДОПМОЩНОСТИ ПО УКРАИНСКОМУ ТРАНЗИТУ ЧЕРЕЗ СТАНЦИЮ СУДЖА НА 2 КВ 22Г
ГАЗПРОМ НЕ СТАЛ БРОНИРОВАТЬ ДОПМОЩНОСТИ ПО УКРАИНСКОМУ ТРАНЗИТУ ЧЕРЕЗ СТАНЦИЮ СУДЖА НА 3 КВ 22
ГАЗПРОМ НЕ СТАЛ БРОНИРОВАТЬ ДОПМОЩНОСТИ ПО УКРАИНСКОМУ ТРАНЗИТУ ЧЕРЕЗ СТАНЦИЮ СУДЖА НА 1 КВ 22Г
ГАЗПРОМ НЕ СТАЛ БРОНИРОВАТЬ ДОПМОЩНОСТИ ПО УКРАИНСКОМУ ТРАНЗИТУ ЧЕРЕЗ СТАНЦИЮ СУДЖА НА 2 КВ 22Г
ГАЗПРОМ НЕ СТАЛ БРОНИРОВАТЬ ДОПМОЩНОСТИ ПО УКРАИНСКОМУ ТРАНЗИТУ ЧЕРЕЗ СТАНЦИЮ СУДЖА НА 3 КВ 22
⚡️🇺🇸#APO #отчетность
Apollo GLobal Management reports third quarter 2021 results
Non-GAAP EPS of $1.71 beats by $0.61.
Management Fees of $474.54M misses by $73.23M.
Total Assets Under Management of $481.1B.
Fee-Generating AUM (“FGAUM”) of $361.3B
#дивиденд declared a cash dividend of $0.50
Apollo GLobal Management reports third quarter 2021 results
Non-GAAP EPS of $1.71 beats by $0.61.
Management Fees of $474.54M misses by $73.23M.
Total Assets Under Management of $481.1B.
Fee-Generating AUM (“FGAUM”) of $361.3B
#дивиденд declared a cash dividend of $0.50
💥🇺🇸#MRNA
Moderna - сотрудничество с Metagenomi по генным технологиям
Moderna and Metagenomi Establish Collaboration to Develop Next-Generation in Vivo Gene Editing Therapeutics
Moderna - сотрудничество с Metagenomi по генным технологиям
Moderna and Metagenomi Establish Collaboration to Develop Next-Generation in Vivo Gene Editing Therapeutics